BDX - Becton Dickinson & Co.
(NaN%)
Sell
Moderate Growth but Declining●Stock Price Very High
45%
based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 6.43%
Operating Income Growth is 7.96%
Net Income Growth is -24.03%
Earnings Per Share (EPS) Growth is -23.95%
Net Margin is 5.33%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 0.94
Debt Ratio is 0.22
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.34
Cash Flow is MODERATE
Cash from Operations Growth is 44.03%
Capital Expenditure is High
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Becton Dickinson & Co. (BDX) - https://www.bd.com/
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others.Exchange - NEW YORK STOCK EXCHANGE INC.
Industry - Surgical and Medical Instrument Manufacturing
Sector - Manufacturing
CEO - Thomas Polen
Employees - 77,000
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2026 and future.
Know the Stock © 2026 and future.